Home / Innere Medizin / Hämatologie und internistische Onkologie / ESMO 2019: Große Fortschritte bei der Immuntherapie des Blasenkarzinoms
Univ.-Prof. Dr. Shahrokh Shariat

ESMO 2019: Große Fortschritte bei der Immuntherapie des Blasenkarzinoms

Der diesjährige ESMO brachte für Univ.-Prof. Dr. Shahrokh Shariat, Universitätsklinik für Urologie, Wien, viele Neuerungen bei der Immuntherapie sowie bei Antikörper-Wirkstoff-Konjugaten.

Cookies aktivieren

Um das Video anzusehen, müssen Sie Statistikcookies akzeptieren.

Einstellungen verwalten


  • Van der Heijden MS et al. Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO) #904PD
  • Necchi A et al. Multiple-cohort analysis investigating FGFR3 alteration as a predictor of non-response to neoadjuvant pembrolizumab (pembro) in muscle-invasive bladder cancer (MIBC). #905PD
  • Grande E et al. IMvigor130: efficacy and safety from a Phase 3 study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). #LBA14_PR
  • Tagawa S et al. Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy. # LBA55
  • Petrylak DP et al. EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors. # LBA4505
  • Hoimes CJ et al. EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. #901O
  • Powles T et al. An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies. #902O
  • Szabados B et al. Urothelial cancer: Bladder-preserving strategies followed by systemic relapse

ESMO Congress 2019